Overall market sentiment has been down on Marker Therapeutics Inc (MRKR) stock lately. MRKR receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.
Marker Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on MRKR!
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With MRKR Stock Today?
Marker Therapeutics Inc (MRKR) stock is trading at $6.11 as of 10:23 AM on Monday, Sep 11, a gain of $0.59, or 10.69% from the previous closing price of $5.52. The stock has traded between $6.00 and $6.80 so far today. Volume today is above average. So far 137,390 shares have traded compared to average volume of 105,149 shares.
To see InvestorsObserver's Sentiment Score for Marker Therapeutics Inc click here.
More About Marker Therapeutics Inc
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
Click Here to get the full Stock Report for Marker Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
